CIK 0001664710 · Non-accelerated filer<br>Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 811173868
- Phone
- 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Open-market buy Director bought 1,000 shares at $11.70 ($11,700)
- 4 Option exercise CHIEF EXECUTIVE OFFICER acquired 55,000 shares (option exercise)
- 4/A Derivatives Options or other derivatives
- 4 Grant or award Director acquired 13,215 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 2,000 shares at $11.21 ($22,420)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale CHIEF EXECUTIVE OFFICER sold 7,015 shares at $16.17 ($113,433)
- 4 Open-market sale Chief Science Officer sold 3,873 shares at $16.35 ($63,324)
- 4 Open-market sale SVP, General Counsel sold 4,745 shares at $16.35 ($77,581)
- 4 Open-market sale CHIEF FINANCIAL OFFICER sold 4,739 shares at $16.35 ($77,483)
- 4 Derivatives Options or other derivatives
- 4 Returned to the company Director returned 214,522 shares (to the company)
- 4 Returned to the company Director returned 214,522 shares (to the company)
- 4 Returned to the company Director returned 322,021 shares (to the company)
- 4 Open-market sale 10% owner sold 4,787,331 shares at $17.75 ($84,975,125)
- 4 Open-market sale 10% owner sold 5,389,264 shares at $17.75 ($95,659,436)
Page 2 of 11 · 206 filings